In the trial, inecalcitol was 11 times potent than a naturally active metabolite of vitamin D, calcitriol in suppressing the growth in-vitro of the human hormone-dependent prostate cancer cell line named LNCaP
The company said inecalcitol was dosed at 1.3mg/kg by intraperitoneal injection three times per week for 42 days to nude mice bearing LNCaP xenografts in the trial.
The results of the trial also suggested that, in-vivo, inecalcitol was 480 times less toxic than calcitriol in mice.